A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma

• DOI: 10.7717/peerj.7125
• Publication Date: 2019-06-17T04:03:01Z
• Authors: Xiang Wang; Zhijie Xu; Xi Chen; Xinxin Ren; Jie Wei; Shuyi Zhou; Xue Yang; Shuangshuang Zeng; Long Qian; Geting Wu; Zhicheng Gong; Yuanliang Yan
• Keywords: Lung adenocarcinoma; 0303 health sciences; QH301-705.5; Bioinformatics; R; Expression; NTRK2; Prognosis; 3. Good health; 03 medical and health sciences; Diagnosis; Medicine; Biology (General)

Neurotrophic receptor tyrosine kinase 2 (NTRK2) is a member of the tropomyosin family associated with tumor development. However, detailed function NTRK2 in lung cancer, especially adenocarcinoma (LUAD), still not fully understood. Here, we investigated effects on LUAD biology. Through analyzing bioinformatics data derived from several databases, such as Oncomine, Gene Expression Profiling Interactive Analysis and UALCAN, found that expression was significantly decreased tissues. Clinical acquired Wanderer database, which linked to The Cancer Genome Atlas demonstrated methylation site were related clinical characteristics prognosis LUAD. Furthermore, increased remarkably after treatment protein B (AKT) inhibitor MK2206 anticancer agent actinomycin D. Functional enrichment analysis NTRK2-associated coexpression genes further conducted. Together, our results suggested downregulated might be used diagnostic prognostic evaluation patients, or potential therapeutic target for